BioMarin's new Executive Vice President and Chief R&D Officer, Greg Friberg discusses his career journey and what brought him to BioMarin.
Q2 2024 Earnings Report
Living with PKU: Jonathan’s Story
Living with PKU: Jonathan’s Story
BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
BioMarin Reports Record Financial Results for the First Quarter 2024
Where Are They Now? Catching Up with Alumni of Our RARE Scholars Program
